VivoSim Labs, Inc. (NASDAQ: VIVS) has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds. The private placement involves the sale of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants at a combined price of $0.85 per share. The warrants, exercisable following shareholder approval, have a five-year term from the initial exercise date and an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company agreed to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, pending customary closing conditions. VivoSim plans to use the net proceeds for working capital and general corporate purposes. The securities were issued in a private placement exempt from Securities Act registration requirements, and the company has committed to filing a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction. For more details, view the full press release at https://ibn.fm/7Ov0B.
This capital infusion comes at a pivotal time for VivoSim, a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The company offers partners liver and intestinal toxicology insights using new approach methodologies (NAM) models. VivoSim anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration’s roadmap to refine animal testing requirements in favor of non-animal NAM methods. The company operates from San Diego, California, and more information is available at https://vivosim.ai/.
The private placement underscores continued investor interest in biotechnology firms that align with regulatory shifts toward alternative testing methods. By securing funding from a healthcare-focused institutional investor, VivoSim gains financial resources to advance its NAM-based services. The warrant amendments and pricing indicate a strategic effort to incentivize long-term investment while providing the company with flexible capital. The transaction’s structure, including the resale registration statement, aims to facilitate liquidity for investors in the public market. As VivoSim progresses, its ability to leverage these funds for operational growth and market expansion will be crucial in a competitive landscape where non-animal testing methods are gaining traction.
